JP2019502680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502680A5 JP2019502680A5 JP2018531058A JP2018531058A JP2019502680A5 JP 2019502680 A5 JP2019502680 A5 JP 2019502680A5 JP 2018531058 A JP2018531058 A JP 2018531058A JP 2018531058 A JP2018531058 A JP 2018531058A JP 2019502680 A5 JP2019502680 A5 JP 2019502680A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- imidazo
- pyrimidin
- tetrahydroquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 123
- -1 tetrahydrocinnolinyl Chemical group 0.000 claims 47
- 125000000753 cycloalkyl group Chemical group 0.000 claims 38
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000001188 haloalkyl group Chemical group 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 27
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000004438 haloalkoxy group Chemical group 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 12
- 125000004193 piperazinyl group Chemical group 0.000 claims 12
- 125000002393 azetidinyl group Chemical group 0.000 claims 10
- 125000002757 morpholinyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000003386 piperidinyl group Chemical group 0.000 claims 10
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 10
- 125000001544 thienyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 239000004305 biphenyl Substances 0.000 claims 7
- 235000010290 biphenyl Nutrition 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 7
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 125000001425 triazolyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- IFVOHRLNAVYUBX-UUKMXZOPSA-N (8S)-N-[[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[2,3-c]pyrrol-5-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CC3CCNC3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 IFVOHRLNAVYUBX-UUKMXZOPSA-N 0.000 claims 2
- CPSBIOBWVCTGGQ-LBAQZLPGSA-N (8S)-N-[[5-(3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1OCCN2C1CN(CC2)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C CPSBIOBWVCTGGQ-LBAQZLPGSA-N 0.000 claims 2
- QHXULMRXASKLHF-KVZIAJEVSA-N (8S)-N-[[5-(3,6-diazabicyclo[3.2.0]heptan-3-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C12CN(CC2NC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C QHXULMRXASKLHF-KVZIAJEVSA-N 0.000 claims 2
- BWASTCHPIZZPOG-CKHPTIKVSA-N (8S)-N-methyl-N-[[5-(1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CC3CCN(C)C3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 BWASTCHPIZZPOG-CKHPTIKVSA-N 0.000 claims 2
- VEYRVHBWYMJASJ-IRQNMHNUSA-N (8S)-N-methyl-N-[[5-(1-methyl-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b]pyridin-6-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CC3CCCN(C)C3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 VEYRVHBWYMJASJ-IRQNMHNUSA-N 0.000 claims 2
- YGVNKXNCNWWXGL-CGAIIQECSA-N (8S)-N-methyl-N-[[5-(3-phenylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CC(NCC2)C2=CC=CC=C2)C=1 YGVNKXNCNWWXGL-CGAIIQECSA-N 0.000 claims 2
- RMXJVGZWTJMJKQ-INIZCTEOSA-N (4S)-N-methyl-N-[(5-piperazin-1-ylimidazo[1,2-c]pyrimidin-2-yl)methyl]-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCNCC2)=N1)[C@H]1CCOC2=C1N=CC=C2 RMXJVGZWTJMJKQ-INIZCTEOSA-N 0.000 claims 1
- FHNOXJUXHNIMEU-KRWDZBQOSA-N (8S)-N-[(7-chloro-5-piperazin-1-ylimidazo[1,2-c]pyrimidin-2-yl)methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound ClC1=CC=2N(C(=N1)N1CCNCC1)C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C FHNOXJUXHNIMEU-KRWDZBQOSA-N 0.000 claims 1
- FSBJWIFGTIJMBU-SFHVURJKSA-N (8S)-N-[(7-methoxy-5-piperazin-1-ylimidazo[1,2-c]pyrimidin-2-yl)methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound COC1=CC=2N(C(=N1)N1CCNCC1)C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C FSBJWIFGTIJMBU-SFHVURJKSA-N 0.000 claims 1
- PXOBFQBPRBONFP-MNLRITNHSA-N (8S)-N-[[5-(1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N1C2C(CCC1)CN(C2)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C PXOBFQBPRBONFP-MNLRITNHSA-N 0.000 claims 1
- SYCJZZJWNRKWAT-KEKNWZKVSA-N (8S)-N-[[5-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN3CCCCC3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 SYCJZZJWNRKWAT-KEKNWZKVSA-N 0.000 claims 1
- FIGMUWNNIJLWCI-QLOJAFMTSA-N (8S)-N-[[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CC3CNCC3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 FIGMUWNNIJLWCI-QLOJAFMTSA-N 0.000 claims 1
- FEKAPINKCFNKFT-DAFXYXGESA-N (8S)-N-[[5-(3-aminopyrrolidin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound NC1CN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C FEKAPINKCFNKFT-DAFXYXGESA-N 0.000 claims 1
- ANQGHJJBZQPELL-VWLOTQADSA-N (8S)-N-[[5-(4-benzylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C(C1=CC=CC=C1)N1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C ANQGHJJBZQPELL-VWLOTQADSA-N 0.000 claims 1
- NYYSZAFJFOWCRE-QFIPXVFZSA-N (8S)-N-[[5-(4-cyclobutylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1(CCC1)N1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C NYYSZAFJFOWCRE-QFIPXVFZSA-N 0.000 claims 1
- XQVBYEARLDIBAE-DEOSSOPVSA-N (8S)-N-[[5-(4-cyclohexylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1(CCCCC1)N1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C XQVBYEARLDIBAE-DEOSSOPVSA-N 0.000 claims 1
- NCTFMMKOVGUVQU-FQEVSTJZSA-N (8S)-N-[[5-(4-ethylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCN1CCN(CC1)c1nccc2nc(CN(C)[C@H]3CCCc4cccnc34)cn12 NCTFMMKOVGUVQU-FQEVSTJZSA-N 0.000 claims 1
- VHPZQGAERZKKAU-SFHVURJKSA-N (8S)-N-[[5-(6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN3C=NN=C3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 VHPZQGAERZKKAU-SFHVURJKSA-N 0.000 claims 1
- GNISBZINWLBVRK-IBGZPJMESA-N (8S)-N-[[5-(6,8-dihydro-5H-imidazo[1,2-a]pyrazin-7-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N=1C=CN2C=1CN(CC2)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C GNISBZINWLBVRK-IBGZPJMESA-N 0.000 claims 1
- XLFOKULIOUVDQY-QKLQHJQFSA-N (8S)-N-[[5-[(3R,5S)-3,5-dimethylpiperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C[C@H]1CN(C[C@H](N1)C)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C XLFOKULIOUVDQY-QKLQHJQFSA-N 0.000 claims 1
- WLNRVVQWSVGANM-JBACZVJFSA-N (8S)-N-[[5-[(7S,8aS)-7-fluoro-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound F[C@H]1C[C@@H]2N(CCN(C2)C2=NC=CC=3N2C=C(N=3)CN([C@H]2CCCC=3C=CC=NC2=3)C)C1 WLNRVVQWSVGANM-JBACZVJFSA-N 0.000 claims 1
- IHXUHJJGTURPBK-SFTDATJTSA-N (8S)-N-[[5-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN3CCC[C@H]3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 IHXUHJJGTURPBK-SFTDATJTSA-N 0.000 claims 1
- UGGDWXMDOLJGGU-ANYOKISRSA-N (8S)-N-[[5-[3-(dimethylamino)pyrrolidin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(C)C1CCN(C1)C1=NC=CC2=NC(CN(C)[C@H]3CCCC4=C3N=CC=C4)=CN12 UGGDWXMDOLJGGU-ANYOKISRSA-N 0.000 claims 1
- QNWZSXRYUMGRHQ-NRFANRHFSA-N (8S)-N-[[5-[4-(1H-imidazol-2-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=NC=CN3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 QNWZSXRYUMGRHQ-NRFANRHFSA-N 0.000 claims 1
- DHTOALAOSQLXGE-FQEVSTJZSA-N (8S)-N-[[5-[4-(2-aminoethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CCN)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 DHTOALAOSQLXGE-FQEVSTJZSA-N 0.000 claims 1
- QHMGWUIDNJPKKS-FQEVSTJZSA-N (8S)-N-[[5-[4-(2-fluoroethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CCF)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 QHMGWUIDNJPKKS-FQEVSTJZSA-N 0.000 claims 1
- OJGQKLCBXDYYIJ-DEOSSOPVSA-N (8S)-N-[[5-[4-(3-chlorophenyl)sulfonylpiperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound ClC=1C=C(C=CC=1)S(=O)(=O)N1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C OJGQKLCBXDYYIJ-DEOSSOPVSA-N 0.000 claims 1
- RRWKZWAJLJOSDO-DEOSSOPVSA-N (8S)-N-[[5-[4-(benzenesulfonyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC2)S(=O)(=O)C2=CC=CC=C2)=N1)[C@H]1CCCC2=C1N=CC=C2 RRWKZWAJLJOSDO-DEOSSOPVSA-N 0.000 claims 1
- QRBFPBOGZSHACW-DEOSSOPVSA-N (8S)-N-[[5-[4-(cyclopentylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1(CCCC1)CN1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C QRBFPBOGZSHACW-DEOSSOPVSA-N 0.000 claims 1
- QCKVLNRMSRMRNG-QFIPXVFZSA-N (8S)-N-[[5-[4-(cyclopropylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3CC3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 QCKVLNRMSRMRNG-QFIPXVFZSA-N 0.000 claims 1
- GELUIMKKZCGLLC-QHCPKHFHSA-N (8S)-N-[[5-[4-(furan-2-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound O1C(=CC=C1)CN1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C GELUIMKKZCGLLC-QHCPKHFHSA-N 0.000 claims 1
- ZPZXKZCIUXHFDU-MHZLTWQESA-N (8S)-N-[[5-[4-[[4-(dimethylamino)phenyl]methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(C1=CC=C(C=C1)CN1CCN(CC1)C1=NC=CC=2N1C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C)C ZPZXKZCIUXHFDU-MHZLTWQESA-N 0.000 claims 1
- YVFYATSBHMMITD-IBGZPJMESA-N (8S)-N-[[7-methoxy-5-(4-methylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound COc1cc2nc(CN(C)[C@H]3CCCc4cccnc34)cn2c(n1)N1CCN(C)CC1 YVFYATSBHMMITD-IBGZPJMESA-N 0.000 claims 1
- YPOGGICGTBXUAW-HNNXBMFYSA-N (8S)-N-methyl-N-[(5-methylsulfanylimidazo[1,2-c]pyrimidin-2-yl)methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)SC)C=1 YPOGGICGTBXUAW-HNNXBMFYSA-N 0.000 claims 1
- AHIGYKYVVYUNAV-SFHVURJKSA-N (8S)-N-methyl-N-[(5-morpholin-4-ylimidazo[1,2-c]pyrimidin-2-yl)methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCOCC2)=N1)[C@H]1CCCC2=C1N=CC=C2 AHIGYKYVVYUNAV-SFHVURJKSA-N 0.000 claims 1
- OSMYWFFIBKMYSD-GRERDSQWSA-N (8S)-N-methyl-N-[[5-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CC3CN(C)CC3C2)=N1)[C@H]1CCCC2=C1N=CC=C2 OSMYWFFIBKMYSD-GRERDSQWSA-N 0.000 claims 1
- RKUCPMGCBOAYKR-IBGZPJMESA-N (8S)-N-methyl-N-[[5-(4-methylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(Cc1cn2c(nccc2n1)N1CCN(C)CC1)[C@H]1CCCc2cccnc12 RKUCPMGCBOAYKR-IBGZPJMESA-N 0.000 claims 1
- AANGCPZMXBIIDX-IBGZPJMESA-N (8S)-N-methyl-N-[[5-(4-methylsulfonylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC2)S(C)(=O)=O)=N1)[C@H]1CCCC2=C1N=CC=C2 AANGCPZMXBIIDX-IBGZPJMESA-N 0.000 claims 1
- ZJPHXNDCLXBJBW-NRFANRHFSA-N (8S)-N-methyl-N-[[5-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)N1CCN(CC1)C1=NC=CC2=NC(CN(C)[C@H]3CCCC4=C3N=CC=C4)=CN12 ZJPHXNDCLXBJBW-NRFANRHFSA-N 0.000 claims 1
- NBHTXLQJGFMSDW-NRFANRHFSA-N (8S)-N-methyl-N-[[5-(4-propan-2-ylsulfonylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)S(=O)(=O)N1CCN(CC1)C1=NC=CC2=NC(CN(C)[C@H]3CCCC4=C3N=CC=C4)=CN12 NBHTXLQJGFMSDW-NRFANRHFSA-N 0.000 claims 1
- RFDXAXKKTHINBT-QHCPKHFHSA-N (8S)-N-methyl-N-[[5-(4-pyridin-3-ylsulfonylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC2)S(=O)(=O)C2=CC=CN=C2)=N1)[C@H]1CCCC2=C1N=CC=C2 RFDXAXKKTHINBT-QHCPKHFHSA-N 0.000 claims 1
- CMHGUYMQOOQIJI-NRFANRHFSA-N (8S)-N-methyl-N-[[5-(4-thiophen-2-ylsulfonylpiperazin-1-yl)imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCN(CC2)S(=O)(=O)C=2SC=CC=2)C=1 CMHGUYMQOOQIJI-NRFANRHFSA-N 0.000 claims 1
- NUWLUVUYKVXYLX-UEXGIBASSA-N (8S)-N-methyl-N-[[5-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C[C@H]1CN(C[C@@H](C)N1C)c1nccc2nc(CN(C)[C@H]3CCCc4cccnc34)cn12 NUWLUVUYKVXYLX-UEXGIBASSA-N 0.000 claims 1
- KRXQOQBUAKHXPX-NRFANRHFSA-N (8S)-N-methyl-N-[[5-[4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=NC=CS3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 KRXQOQBUAKHXPX-NRFANRHFSA-N 0.000 claims 1
- ZFBFBBIQHXTWDQ-DEOSSOPVSA-N (8S)-N-methyl-N-[[5-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCN(CC2)C2CCN(CC2)C)C=1 ZFBFBBIQHXTWDQ-DEOSSOPVSA-N 0.000 claims 1
- SZGHHZXCNFIIJZ-IBGZPJMESA-N (8S)-N-methyl-N-[[5-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC(F)(F)F)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 SZGHHZXCNFIIJZ-IBGZPJMESA-N 0.000 claims 1
- WFUDWZQGVPVMFG-FQEVSTJZSA-N (8S)-N-methyl-N-[[5-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCN(CC2)CCC(F)(F)F)C=1 WFUDWZQGVPVMFG-FQEVSTJZSA-N 0.000 claims 1
- YPLVPBAAEABBJC-QHCPKHFHSA-N (8S)-N-methyl-N-[[5-[4-(3-methylbutyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)CCN1CCN(CC1)C1=NC=CC2=NC(CN(C)[C@H]3CCCC4=C3N=CC=C4)=CN12 YPLVPBAAEABBJC-QHCPKHFHSA-N 0.000 claims 1
- IUWBEAXSUOGSFS-WCSIJFPASA-N (8S)-N-methyl-N-[[5-[4-(oxolan-2-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3CCCO3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 IUWBEAXSUOGSFS-WCSIJFPASA-N 0.000 claims 1
- SXXFPTBEMTVDDG-AKRCKQFNSA-N (8S)-N-methyl-N-[[5-[4-(oxolan-3-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3CCOC3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 SXXFPTBEMTVDDG-AKRCKQFNSA-N 0.000 claims 1
- LPNWQENNSQKLRN-DEOSSOPVSA-N (8S)-N-methyl-N-[[5-[4-(pyridin-2-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=NC=CC=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 LPNWQENNSQKLRN-DEOSSOPVSA-N 0.000 claims 1
- BISMTIZYXADOPJ-DEOSSOPVSA-N (8S)-N-methyl-N-[[5-[4-(pyridin-3-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC=CN=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 BISMTIZYXADOPJ-DEOSSOPVSA-N 0.000 claims 1
- GKSSVXGPAZGLKX-DEOSSOPVSA-N (8S)-N-methyl-N-[[5-[4-(pyridin-4-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC=NC=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 GKSSVXGPAZGLKX-DEOSSOPVSA-N 0.000 claims 1
- HJUOUQNIOSSDSQ-QHCPKHFHSA-N (8S)-N-methyl-N-[[5-[4-(thiophen-2-ylmethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC=CS3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 HJUOUQNIOSSDSQ-QHCPKHFHSA-N 0.000 claims 1
- RKUCPMGCBOAYKR-COJYBMMNSA-N (8S)-N-methyl-N-[[5-[4-(trideuteriomethyl)piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCN(CC2)C([2H])([2H])[2H])C=1 RKUCPMGCBOAYKR-COJYBMMNSA-N 0.000 claims 1
- ZOZDIVKOTRPSAJ-QFIPXVFZSA-N (8S)-N-methyl-N-[[5-[4-[(1-methylimidazol-2-yl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=NC=CN3C)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 ZOZDIVKOTRPSAJ-QFIPXVFZSA-N 0.000 claims 1
- IAYHNBZPDOKUDP-DEOSSOPVSA-N (8S)-N-methyl-N-[[5-[4-[(1-methylpyrrol-2-yl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCN(CC2)CC=2N(C=CC=2)C)C=1 IAYHNBZPDOKUDP-DEOSSOPVSA-N 0.000 claims 1
- LUKQNQYSNAEGAD-QHCPKHFHSA-N (8S)-N-methyl-N-[[5-[4-[(3-methylimidazol-4-yl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CN=CN3C)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 LUKQNQYSNAEGAD-QHCPKHFHSA-N 0.000 claims 1
- SGHPJFSCEVQMQM-SANMLTNESA-N (8S)-N-methyl-N-[[5-[4-[(3-methylphenyl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC(C)=CC=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 SGHPJFSCEVQMQM-SANMLTNESA-N 0.000 claims 1
- NXFIZMWFMLLHEO-HKBQPEDESA-N (8S)-N-methyl-N-[[5-[4-[(3-phenoxyphenyl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC(OC4=CC=CC=C4)=CC=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 NXFIZMWFMLLHEO-HKBQPEDESA-N 0.000 claims 1
- HZQHIFLZKQJVJY-SANMLTNESA-N (8S)-N-methyl-N-[[5-[4-[(4-methylphenyl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC=C(C)C=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 HZQHIFLZKQJVJY-SANMLTNESA-N 0.000 claims 1
- SGKJKILHMYYXNS-HKBQPEDESA-N (8S)-N-methyl-N-[[5-[4-[(4-phenylphenyl)methyl]piperazin-1-yl]imidazo[1,2-c]pyrimidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC3=CC=C(C=C3)C3=CC=CC=C3)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 SGKJKILHMYYXNS-HKBQPEDESA-N 0.000 claims 1
- NCPTUBRVAQWRSB-FQEVSTJZSA-N 1-[4-[2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-c]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CC2)C(C)=O)=N1)[C@H]1CCCC2=C1N=CC=C2 NCPTUBRVAQWRSB-FQEVSTJZSA-N 0.000 claims 1
- UENRYYSJOAZKNV-FQEVSTJZSA-N 2-[4-[2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-c]pyrimidin-5-yl]piperazin-1-yl]ethanol Chemical compound CN(CC1=CN2C(C=CN=C2N2CCN(CCO)CC2)=N1)[C@H]1CCCC2=C1N=CC=C2 UENRYYSJOAZKNV-FQEVSTJZSA-N 0.000 claims 1
- FIAKFJOKXMPQTR-KRWDZBQOSA-N 2-[[4-aminobutyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-6H-imidazo[1,2-c]pyrimidin-5-one Chemical compound NCCCCN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)O)C=1 FIAKFJOKXMPQTR-KRWDZBQOSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- UKOFAXWNKGCWRI-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)imidazo[1,2-c]pyrimidine-2-carbaldehyde Chemical compound CN1CCN(CC1)C1=NC=CC=2N1C=C(N=2)C=O UKOFAXWNKGCWRI-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 claims 1
- MROQMFAUUWKATN-SFHVURJKSA-N [2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-5-piperazin-1-ylimidazo[1,2-c]pyrimidin-3-yl]methanol Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCNCC2)C=1CO MROQMFAUUWKATN-SFHVURJKSA-N 0.000 claims 1
- MSDSBOZZEQSSNZ-IBGZPJMESA-N [5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-c]pyrimidin-3-yl]methanol Chemical compound CN([C@H]1CCCC=2C=CC=NC1=2)CC=1N=C2N(C(=NC=C2)N2CCN(CC2)C)C=1CO MSDSBOZZEQSSNZ-IBGZPJMESA-N 0.000 claims 1
- AUGVJMFIDKSLFX-FQEVSTJZSA-N [7-methoxy-5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-c]pyrimidin-8-yl]methanol Chemical compound COC1=C(C=2N(C(=N1)N1CCN(CC1)C)C=C(N=2)CN([C@H]1CCCC=2C=CC=NC1=2)C)CO AUGVJMFIDKSLFX-FQEVSTJZSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical group OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- KMQFNRGRKSFZQC-UHFFFAOYSA-N tert-butyl 4-(2-formylimidazo[1,2-c]pyrimidin-5-yl)piperazine-1-carboxylate Chemical compound C(=O)C=1N=C2N(C(=NC=C2)N2CCN(CC2)C(=O)OC(C)(C)C)C=1 KMQFNRGRKSFZQC-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267649P | 2015-12-15 | 2015-12-15 | |
| US62/267,649 | 2015-12-15 | ||
| PCT/US2016/066575 WO2017106291A1 (en) | 2015-12-15 | 2016-12-14 | Cxcr4 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502680A JP2019502680A (ja) | 2019-01-31 |
| JP2019502680A5 true JP2019502680A5 (enExample) | 2020-01-23 |
| JP6856648B2 JP6856648B2 (ja) | 2021-04-07 |
Family
ID=57755467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531058A Active JP6856648B2 (ja) | 2015-12-15 | 2016-12-14 | Ｃｘｃｒ４受容体アンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10450318B2 (enExample) |
| EP (1) | EP3390406A1 (enExample) |
| JP (1) | JP6856648B2 (enExample) |
| KR (1) | KR102738306B1 (enExample) |
| CN (1) | CN108602829A (enExample) |
| WO (1) | WO2017106291A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018225556A1 (en) | 2017-02-21 | 2019-10-03 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| CN109553604B (zh) * | 2017-09-25 | 2021-08-27 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用 |
| WO2019183133A1 (en) | 2018-03-19 | 2019-09-26 | Emory University | Pan-Tropic Entry Inhibitors |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0127547D0 (en) * | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| JP2008511669A (ja) * | 2004-09-02 | 2008-04-17 | スミスクライン ビーチャム コーポレーション | 化合物 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP2008524255A (ja) * | 2004-12-17 | 2008-07-10 | スミスクライン ビーチャム コーポレーション | 化学物質 |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1910370B1 (en) | 2005-07-22 | 2015-04-22 | Eli Lilly And Company | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| AR059197A1 (es) * | 2006-01-25 | 2008-03-19 | Smithkline Beecham Corp | Derivados de indazolo piridina para el tratamiento de hiv |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| CN101990432B (zh) | 2008-01-03 | 2016-01-20 | 艾克斯-马赛大学 | 抗hiv治疗期间使用的组合物和方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| MX355418B (es) | 2010-05-04 | 2018-04-18 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| CN103221428B (zh) | 2010-09-09 | 2016-02-10 | 辉瑞公司 | 4-1bb结合分子 |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
-
2016
- 2016-12-14 JP JP2018531058A patent/JP6856648B2/ja active Active
- 2016-12-14 US US15/776,936 patent/US10450318B2/en active Active
- 2016-12-14 KR KR1020187019798A patent/KR102738306B1/ko active Active
- 2016-12-14 CN CN201680081803.1A patent/CN108602829A/zh active Pending
- 2016-12-14 EP EP16823109.0A patent/EP3390406A1/en not_active Withdrawn
- 2016-12-14 WO PCT/US2016/066575 patent/WO2017106291A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10544150B2 (en) | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | |
| JP2019535664A5 (enExample) | ||
| RU2443706C2 (ru) | Фармацевтические соединения | |
| AU2010339423B2 (en) | Therapeutic compounds and related methods of use | |
| KR101466412B1 (ko) | 피롤로피리미딘 화합물 및 그의 용도 | |
| JP2021506923A5 (enExample) | ||
| JP2023549055A (ja) | 複素環式スピロ化合物及びその使用方法 | |
| KR101481872B1 (ko) | Ｊａｋ의 억제제 | |
| US20200392161A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| JP6853782B2 (ja) | 新規二環性複素環化合物 | |
| JP2021506858A5 (enExample) | ||
| CN108137600A (zh) | 作为激酶抑制剂的稠合的吡唑衍生物 | |
| AU2011274192A1 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
| KR102006670B1 (ko) | 신규 이미다조피리다진 화합물 및 그의 용도 | |
| MX2007001399A (es) | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. | |
| JP2012519678A5 (enExample) | ||
| US10065960B2 (en) | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | |
| RU2008145504A (ru) | Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы | |
| JP2019502680A5 (enExample) | ||
| JP2014511355A5 (enExample) | ||
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| HRP20160649T1 (hr) | Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba | |
| WO2019034973A1 (en) | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES | |
| IL305956A (en) | Pharmaceutical material | |
| EA037563B1 (ru) | Новые (гетеро)арил-замещенные пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их |